Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed FCF Margin for 9 consecutive years, with 7835.42% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, FCF Margin fell 735100.0% year-over-year to 7835.42%, compared with a TTM value of 27210.42% through Sep 2025, down 2272529.0%, and an annual FY2024 reading of 11123.81%, down 952100.0% over the prior year.
  • FCF Margin was 7835.42% for Q4 2024 at Avalo Therapeutics, down from 4629.32% in the prior quarter.
  • Across five years, FCF Margin topped out at 37.67% in Q3 2022 and bottomed at 7835.42% in Q4 2024.
  • Average FCF Margin over 5 years is 2168.75%, with a median of 1209.92% recorded in 2022.
  • The sharpest move saw FCF Margin soared 738366bps in 2022, then crashed -735100bps in 2024.
  • Year by year, FCF Margin stood at 960.53% in 2020, then tumbled by -713bps to 7812.79% in 2021, then soared by 95bps to 429.13% in 2022, then fell by -13bps to 484.41% in 2023, then crashed by -1518bps to 7835.42% in 2024.
  • Business Quant data shows FCF Margin for AVTX at 7835.42% in Q4 2024, 4629.32% in Q3 2024, and 484.41% in Q4 2023.